Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIb non-small cell lung cancer.

Lucio Trodella, Rolando Maria D'Angelillo, Sara Ramella, Alfredo Cesario, Salvatore Valente, Pierluigi Granone, L. Trodella, F. De Marinis, R. M. D'Angelillo, S. Ramella, F. Nelli, M. R. Migliorino, F. Cellini, S. Bonassi, P. Russo, E. Cortesi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

BACKGROUND: To evaluate feasibility and safety of induction three-drugs combination chemotherapy and concurrent radio-chemotherapy in stage IIIB NSCLC. PATIENTS AND METHODS: Patients with stage IIIB NSCLC were treated with three courses of induction chemotherapy, cisplatin 50 mg/m(2), paclitaxel 125 mg/m(2) and gemcitabine 1000 mg/m(2) on days 1,8 of every 21 day cycle. Patients without distant progressive disease were then treated with radiotherapy and concurrent weekly gemcitabine (250 mg/m(2)). Toxicity and response of radio-chemotherapy treatment have been assessed. RESULTS: Between Jan 01 and Nov 02, 46 patients were enrolled. Grade 3+ hematological and non-hematological toxicity during the induction phase were 41.3% and 13.1%, respectively. In 38 patients a Clinical Response or Stable Disease was recorded and these patients underwent to concurrent radio-chemotherapy. Grade 3+ hematological and non-hematological toxicities were 8.2% in this group. Further response was observed in 66% of patients. Overall median survival time was 17.8 months, with a 3-year survival rates of 23%. CONCLUSION: Three-drugs induction chemotherapy and concurrent radio-chemotherapy with weekly gemcitabine in locally advanced stage IIIB NSCLC is feasible and safe.
Original languageEnglish
Pages (from-to)331-338
Number of pages8
JournalLung Cancer
Publication statusPublished - 2006

Keywords

  • lung

Fingerprint Dive into the research topics of 'Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIb non-small cell lung cancer.'. Together they form a unique fingerprint.

Cite this